Viventia Biotechnologies Inc. is a privately held biopharmaceutical company specializing in the discovery and development of a new generation of advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer.
Viventia is employing its novel monoclonal antibody discovery and development platforms to discover, validate and advance a portfolio of new antibody products based on proprietary oncology drug targets.
Viventia offers a comprehensive, integrated ‘bench to bedside’ R&D engine, capable of identifying new targets, developing human antibodies against those targets, optimizing those antibodies to have favorable therapeutic properties and producing those antibodies for use in clinical trials with a view to commercialization.
Viventia has conceived, built and successfully operationalized these platform technologies and now routinely isolates and screens hundreds of thousands of human monoclonal antibodies annually. This discovery engine has identified to date over 12 new cancer drug targets and their associated antibody drug leads.
For more information, please contact:
Dr. Glen MacDonald, Vice President Research & Operations gmacdonald@viventia.com
(204) 478-1023
147 Hamelin Street, Winnipeg, MB, Canada, R3T 3Z1
This page made possible by LSAM's exclusive sector directory sponsor.
